Anti-CD3 activated vaccine-primed lymphocytes (University of Michigan)

N/A

Report date: 2022/11/27 16:45:02

Base Information

Drug NameAnti-CD3 activated vaccine-primed lymphocytes (University of Michigan)
Drug Alias Namevaccine-primed lymph node (VPLN) cellsmonoclonal antiobody activated vaccine-primed lymphocytes (cancer)VPLN tumor vaccine
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionT lymphocytes stimulantsImmunostimulantsAnti-CD3
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Michigan
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A